~~<i id='3F8F41ADE4'><strike id='3F8F41ADE4'><tt id='3F8F41ADE4'><pre id='3F8F41ADE4'></pre></tt></strike></i>~~

Home» focus» explore

explore

author：fashion 2025-09-28 15:56:20 Page View：79

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Erich Jarvis studies song birds to learn about human stuttering
Next article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

explore

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

With Wegovy coverage, Medicare patients may face high costs

ApersonholdsaWegovyinjectionpen.KayanaSzymczakforSTATMedicareconfirmedthisweekthatitwillcoverNovoNor

23andMe had bad news about my health. I wish a person had delivered it

ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

Readout Newsletter: Amylyx, Aurinia, and IQVIA

AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo